An Evaluation of the Efficacy of adding Clonidine as Adjuvant to Bupivacaine as Compared to Dexmedetomidine as Adjuvant to Bupivacaine in Supraclavicular Brachial Plexus Blocks for Upper Limb Surgeries by Saravanagopi, V
AN EVALUATION OF THE EFFICACY OF ADDING 
CLONIDINE AS ADJUVANT TO BUPIVACAINE AS 
COMPARED TO DEXMEDETOMIDINE AS ADJUVANT TO 
BUPIVACAINE IN SUPRACLAVICULAR BRACHIAL PLEXUS 
BLOCKS FOR UPPER LIMB SURGERIES 
 
Dissertation submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
In partial fulfillment for the award of the degree of 
DOCTOR OF MEDICINE 
IN 
ANAESTHESIOLOGY 
 
BRANCH X 
     
     
 
 
 
 
 
 
 
 
DEPARTMENT OF ANAESTHESIOLOGY 
THANJAVUR MEDICAL COLLEGE 
THANJAVUR – 613004. 
 
APRIL 2015 
 CERTIFICATE 
 
This is to certify that the dissertation entitled, “EFFICACY OF  ADDING 
CLONIDINE AS ADJUVANT TO BUPIVACAINE AS COMPARED TO 
DEXMEDITOMIDINE AS ADJUVANT TO BUPIVACAINE IN 
SUPRACLAVICULAR  BRACHIAL  PLEXUS BLOCKS FOR UPPER 
LIMB SURGERIES” submitted by Dr.V.SARAVANAGOPI in partial 
fulfillment for the award of the degree of Doctor of Medicine in Anaesthesiology 
by the Tamilnadu Dr.M.G.R. Medical University, Chennai is a bonafide record of 
the work done by him in the Department of Anaesthesiology, Government 
Thanjavur Medical College, during the academic year 2012-2015. 
 
Prof.Dr.G.Sivakumar  M.D.,D.A., 
Professor, 
Department of Anaesthesiology, 
Thanjavur Medical College, 
Thanjavur 
Prof.Dr.R.Muthukumaran M.D.,D.A., 
Professor & Head of the department, 
Department of Anaesthesiology, 
Thanjavur Medical College, 
Thanjavur 
 
 
 
Place   :                                                                                               
Date    : 
       The Dean,
      Thanjavur Medical College, 
Thanjavur. 
  
 
 DECLARATION 
 
I, DR.V.SARAVANAGOPI, solemnly declare that the dissertation titled 
“EFFICACY OF  ADDING CLONIDINE AS ADJUVANT TO 
BUPIVACAINE AS COMPARED TO DEXMEDITOMIDINE AS 
ADJUVANT TO BUPIVACAINE IN SUPRACLAVICULAR BRACHIAL 
PLEXUS BLOCKS FOR UPPER LIMB SURGERIES” is a bonafide work 
done by me at Thanjavur Medical College Hospital, Thanjavur, during 2012-2015. 
 The dissertation is submitted to “The Tamilnadu Dr. M.G.R. Medical 
University, Chennai”, Tamilnadu as a partial fulfillment for the requirement of 
M.D Degree examinations – Branch -X (Anaesthesiology) to be held in April 
2015.  
 
 
 
Place: Thanjavur 
Date:       (DR.V.SARAVANAGOPI) 
 
 

ACKNOWLEDGEMENT 
 
I am extremely thankful to Dr.MAHADEVAN, M.S., Dean, Thanjavur 
Medical College, for his kind permission to carry out this study. 
I am immensely grateful to Prof.Dr.R.MUTHUKUMARAN, M.D., D.A., The 
professor and Head of the Department of Anaesthesiology, for his concern and 
support in conducting the study. 
I am greatly indebted to my guide Prof.Dr.G.SIVAKUMAR M.D.,D.A, The 
professor, Department of Anaesthesiology, for his inspiration, guidance and 
comments at all stages of this study. 
I am thankful to Dr.S.SAI PRABHA M.D., Assistant professor, Department 
of Anaesthesiology, for her inspiration, guidance and comments at all stages of this 
study. 
I am thankful to all Assistant professors of the department of 
Anaesthesiology, for their guidance and help.  I am thankful to all my colleagues 
for the help rendered in carrying out this dissertation. 
I thank all the patients for  submitting themselves willingly for this study. 
 
(Dr. V.SARAVANAGOPI) 
 
Submission author:
Assignment title:
Submission title:
File name:
File size:
Page count:
Word count:
Character count:
Submission date:
Submission ID:
Digital Receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
The first page of your submissions is displayed below.
Saravanagopi V
TNMGRMU EXAMINATIONS
AN EVALUATION OF THE EFFICAC…
Copy_of_sara_1.docx
254.94K
116
11,973
67,464
12-Oct-2014 03:01PM
454106590
Copyright 2014 Turnitin. All rights reserved.
  
CONTENTS 
S.NO. TOPIC PAGENO. 
1. INTRODUCTION 1 
2. AIM OF THE STUDY 4 
3. APPLIED PHYSIOLOGY 5 
4. ANATOMY OF THE BRACHIAL PLEXUS 13 
5. PHARMACOLOGY OF BUPIVACAINE 20 
6. PHARMACOLOGY OF CLONIDINE AND DEXMEDITOMIDINE 29 
7. REVIEW OF LITERATURE 45 
8. MATERIALS AND METHODS 54 
9. OBSERVATION  AND RESULTS 65 
10. DISCUSSION 96 
11. SUMMARY 102 
12. CONCLUSION 104 
13. BIBLIOGRAPHY 105 
14. MASTER CHART 112 
15. PROFORMA 115 
 
ABSTRACT 
Background and Objectives:  Alpha-2 agonists are mixed with local 
anaesthetic agents to extend the duration of spinal, extradural and peripheral 
nerve blocks. We compared clonidine and dexmedetomidine as an adjuvant to 
local anaesthetic agent in supraclavicular brachial plexus block with respect to 
onset and duration of sensory and motor block and duration of analgesia. 
 Methods: Sixty ASA I and II patients scheduled for elective upper limb 
surgeries under supraclavicular brachial plexus block were divided into two 
equal groups in a randomized, double- blinded fashion. Group C received 
clonidine 1 μg/kg and Group D received dexmedetomidine 1 μg/kg added to 
bupivacaine 0.25% (40ml). Onset and recovery time of sensory and motor block 
and duration of analgesia were studied in both the groups. 
 Results: Duration of sensory block and motor block was 224.50±32.70 and 
307.70±34.91min, respectively, in group C, while it was 414.63±70.35 and 
489.16±72.80 min, respectively, in group D. There was no statistically 
significant difference in onset of sensory block. Onset of motor   block in group 
C was 5.66 ±1.39 minutes .Onset of motor block in group D was 5.40±1.88 
minutes. Onset of motor block in group D is faster than group D; this difference 
was statistically significant.  ‘p’ value < 0.005.   The duration of analgesia (time 
to requirement of rescue analgesia) in group D was 455.96±71.34 min, while in 
group C, it was 263.10±40.53 min. Statistically, this difference was significant 
(P=0.001).  
Conclusion:  
We conclude that addition of 1 µg/kg of dexmedetomidine to 0.25 % 
bupivacaine accelerates the onset of sensory and motor block, prolongs the 
duration of sensory and motor block and the time for rescue analgesia with mild 
sedation without any adverse effects,  when compared to clonidine as an 
adjuvant to bupivacaine in supraclavicular brachial plexus blocks for upper limb 
surgeries   
Key words: Clonidine, dexmedetomidine, supraclavicular block 
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INTRODUCTION 
Pain is an unpleasant sensory and emotional experience associated 
with actual or potential  tissue damage. Theory of pain as a separate and 
distinct sense was definitely formulated by Mortiz S.Schiff in 1858. William 
Halsted and Alfred Hall invented the idea of injecting cocaine into nerve 
trunk in 1884. 
          G. Hirschel performed first percutaneous axillary brachial plexus 
block in 1884. D. Kulenkampff performed supraclavicular brachial plexus 
block in 1911. Lidocaine was synthesized by Lofgreen and Lundquvisit in 
1943. Bupivacaine was synthesized by Ekenstam in 1956. Bupivacaine 
was introduced in clinical practice by Telivuo in 1963.Melzock and Walts 
(1965) propounded the Gate Control Theory of pain. 
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Peripheral nerve blocks provide optimal operating conditions when used 
ideally. They reduce the stress response to surgery and cause least 
interference with the vital physiological functions of the body,when 
compared to other conventional techniques.  Brachial plexus block was first 
performed by William Stewart Halsted in 18891. D. Kulenkampff performed 
supraclavicular brachial plexus block in1911. The main drawback of local 
anaesthetic agents are the delayed onset of action, varying intensity of 
blockade and inadequate post operative pain relief . To overcome these 
drawbacks, various adjuvants were added with local anesthetic solutions. 
Various opioid and non-opioid agents have been studied as adjuvants to 
Brachial Plexus blockade. Clonidine and Dexmedetomidine have shown 
greater affinity for α2 receptors. 
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“The aim of this study is to compare the relative efficacy of Clonidine 
and Dexmedetomidine with Bupivacaine for intra-operative/ post-operative 
analgesia and safety.Addition of alpha 2 adrenergic agonist drugs is 
suggested to improve the local anaesthetic effects by facilitation of C fiber 
blockade and local vasoconstriction or a simple diffusion along the nerve or 
slow retrograde axonal transport in spinal cord. 
Clonidine and dexmedetomidine  possibly amplify  the Na+ channel 
blockade action of local anaesthetic by opening up the K+ channels resulting 
in membrane hyperpolarisation. This study compares clonidine and 
dexmedetomidine as an adjuvant to bupivacaine for brachial plexus block by 
supraclavicular approach for orthopaedic procedures of moderate duration 
using nerve stimulator . The Brachial Plexus is blocked at its most compact 
site (middle of Brachial Plexus) and it results in a homogenous spread of 
anaesthetic drug to cause early and complete block. 
In clinical studies, adding clonidine or dexmedetomidine to local 
anaesthetic solutions improved peripheral nerve blocks by quickening the 
onset time, improving the quality of block during surgery and extending    
post operative analgesia. 
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AIM OF THE STUDY 
 
To evaluate the efficacy of  adding Clonidine as an adjuvant  to 
Bupivacaine as compared to Dexmedetomidine as adjuvant to Bupivacaine in 
supraclavicular brachial plexus blocks for upper limb surgeries, with regards 
to the following parameters: 
a) Onset of sensory block 
b) Duration of sensory block 
c) Onset of motor block 
d) Duration of motor block 
e) Haemodynamic changes(heart rate,NIBP,SPO2) 
f) Level of sedation and complications(if any) 
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APPLIED PHYSIOLOGY 
PHYSIOLOGICAL CONSIDERATION 
      Painful stimuli is transformed from its native form by activated 
nociceptors into electrical signals which are transmitted along corresponding 
nociceptive fibres. These fibres in turn synapse onto II order neurons in the 
spinal cord. These interneurons are located in dorsal horn. At these 
interneurons ,the initial modulation of nociceptive input occurs. From the 
spinal cord, nociceptive input is transmitted to the brain stem, thalamus and 
cortex. 
 
Peripheral neuroanatomy of nociception: 
     A and C fibres are the main peripheral nociceptors. The skin, joints and 
periosteum are richly innervated with A and C nociceptors as well as the non 
nociecptive A and B sensory fibres. 
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      The A fibres are responsible for sensation of first pain, the initial sharp 
pain experienced following an injury.  The C fibres are unmyelinated and are 
responsible for second pain, the slow throbbing burning pain experienced 
following an injury. 
Peripheral neurochemistry and neurotransmitters : 
Inflammatory mediators involved  in pain and  hyperalgesia include 
potassium, substance P, Bradykinins, cytokines, serotonin, histamine and 
prostaglandins. These peripheral neurotransmitters sensitise the peripheral 
nociceptors to pain. 
 
Peripheral alpha 2 receptors : 
 Alpha 2 adrenoreceptors ,located on primary afferent terminals, are on 
neurons in the superficial laminae of the spinal cord, and within several 
brainstem nuclei involved in analgesia, supporting the possibility of analgesic 
action at peripheral, spinal, and brainstem sites. 
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 Clonidine increases both sensory and motor blockade from peripheral 
nerve injection and epidural / spinal injection of local anaesthetics. 
 Clonidine blocks conduction of A gamma and C fibers and increase K+ 
conductance in isolated neurons and increases conduction block of local 
anaesthetics.Local vasoconstriction resulting in reduced absorption from the 
injection site is another point of discussion. But compared with adrenaline as 
adjuvant, it failed to influence plasma levels.This  indicates a direct action on 
nerve. 
 
PAIN PATHWAY 
SPINAL CORD 
 The gray matter of the spinal cord is divided into 10  lamina2. Lamina   
I – IV representing the dorsal horn.  Dorsal horn is capped by the Lissauer’s 
tract which consists of branches of cutaneous C and A  fibres and few 
visceral afferents. 
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Nociceptive fibres ends in  superficial layers of lamina I & II, while the 
non-painful myelinated fibres ends in the deeper layers of lamina III,IV . 
Lamina II has  highest concentration of opioid receptors in the spinal cord.  
Modulation and inhibition of nociception  occurs at this level, by the 
use of opioids (systemic and neuraxial). 
Ascending sensory pathways 
 Peripheral sensory neurons synapse with the secondary interneurons of 
dorsal horn.Axons of non nociceptive secondary neurons travel bilaterally in 
the dorsal columns of the spinal cord as fasciculus cuneatus and fasciculus 
gracilis and synapse in thalamus. 
 The axons of  nociceptive secondary neurons, after synapsing, travel 
contralaterally in  anterolateral aspects of spinal cord as neospinothalamic 
and paleospinothalamic tracts. 
 Neospinothalamic tract carries fine discrimination of pain eg. First 
pain, Intensity and location. 
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 The paleospinothalamic tract synapses in the thalamus, hypothalamus and 
limbic system and plays a role in emotional aspects of pain via limbic system. 
Paleospinothalamic tract responds to  noxiousstimuli.The thalamus has 
multiple connections to limbic system and cortex. 
Descending inhibitory pathways 
 The descending tracts of pain end in the laminas I, II, V of dorsal horn 
from mesencephalon, raphenuclei and reticular tract. The mesencephalon is 
rich in opioid receptors. This area sends excitatory transmissions to the 
rostroventral medulla which sends noradrenaline and serotonin inhibitory 
tracts via the dorsolateral funiculus to lamina I,II,V of spinal cord. 
The noradrenaline and serotonin fibres mediate transmission between  
primary afferents and secondary neurons of the dorsal horn. Enhanced 
activity of these fibres leads to enhanced inhibition of pain transmission. 
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Location of Alpha2 receptors : 
 Alpha 2 receptors are located in the primary afferent terminals, on 
neurons in the superficial laminae of spinal cord and  the brainstem   nuclei. 
Location of opioid receptors (central): 
 Opioid receptors are found in cerebral cortex, limbic cortex ,anterior 
and posterior amygdalae, hippocampus,hypothalamus, medial thalamus, mid 
brain, periaqueductal gray matter, extrapyramidal areas, substantia gelatinosa 
and sympathetic preganglionic neurons. 
 Opioid receptors are also found in cardiac sympathetic fibres, cardiac 
branches of vagus, adrenal medulla, and in the  gastro intestinal tract 
ACTION OF LOCAL ANAESTHETICS ON NERVE FIBRES3 
The primary action of local anaesthetics on nerve is electrical stabilization. 
Large transient increase in Na+ ion permaeability essential for nerve impulse 
propagation is prevented.The resting membrane potential is maintained and 
depolarization is inhibited in response to stimulation. 
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Local anaesthetics block sodium conductance as follows: 
a) Binding of local anaesthetics to voltage gated Na+ channels prevents 
its opening by inhibiting conformational changes that underlie 
activation of the channel. 
b) Local anaesthetics also produce nonspecific expansion of the 
membrane.unfolding of the membrane protein together with 
disordering of lipid componenet of cell membrane causes obstruction 
of Na+ channel. 
 
ACTION OF ALPHA ADRENERGIC AGONISTS 
a) Alpha adreno receptors are located on the afferent terminals of 
peripheral neurons ,neurons in superficial laminae of spinal cord 
and many brainstem nuclei involved in analgesia. 
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b) Dexmedetomine and clonidine inhibits voltage gated  sodium  and 
potassium channels & suppress the action potential generation in 
tonic firing neurons. 
c) Release of acetyl choline in the neuraxial region and blocking of C 
fibres in the peripheral nerves may contribute to pain relief. 
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ANATOMICAL CONSIDERATIONS 
FORMATION OF BRACHIAL  PLEXUS4 
Roots 
The plexus is formed by anterior primary rami of the fifth to eighth 
cervical nerves, together with the bulk of the 1st thoracic nerve (C -8 and T1). 
There is frequently a contribution above from C4 to the 5th cervical root and 
another below from T2 to the 1st thoracic nerve. Occasionally the plexus is 
mainly derived from C4 -8 (Pre –fixed plexus) or from C6 – T2 (post – fixed 
plexus). 
 
Trunks 
The five roots of  plexus emerge from  intervertebral foramina. They 
lie in the space between  anterior and posterior tubercles of the corresponding 
transverse processes. All 5  roots, lie between the scalenus anterior and 
medius. Here roots of C5 &C6 unite into the upper trunk. The root of C7 
continues as the middle trunk and those of C8 and T1 into the lower trunk. 
Then each  of these trunks divides behind the clavicle, into anterior and 
posterior divisions, which unite in axilla to form the cords. 
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Cords 
The six divisions stream into axilla and form three cords, lateral, 
medial and posterior. These cords are composed as follows: 
The union of the anterior divisions of upper and middle trunks forms 
the lateral cord. The continuation of the anterior division of the lower trunks 
represents the medial cord. The posterior cord comprises of all three posterior 
divisions. 
The composition of the brachial plexus can be summarized as follows: 
1. Five roots – the anterior primary rami of C5 to C8& T1 
2. Three trunks. 
a) Upper trunk, C5 & C6 
b) Middle trunk, C7 alone & 
c) Lower trunk, C8 &T1 
3. Six division – each trunk divides into anterior and posterior division.  
4. Three  cords 
a)Lateral cord, the fused anterior divisions of the upper & middle 
trunks (C5 to C7) 
b) Medial cord, anterior division of the lower trunk (C8&T1) 
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c) Posterior cord, formed by  union of posterior division of all  the 
three trunks (C5, T1) 
THE RELATIONS OF THE BRACHIAL PLEXUS 
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TECHNIQUE OF BRACHIAL PLEXUS BLOCK 
 Surgical anaesthesia of the upper extremity and shoulder can be 
obtained at several sites following neural blockade of the brachial plexus. The 
various  approaches are: 
1.Interscalene approach 
2. Supraclavicular approach 
a. Classic approach 
b. Plumb –bob technique 
c. Subclavian perivascular technique 
3. Axillary approach 
4. Infraclavicular approach 
  
17 
 
 
TECHNIQUE OF BLOCKADE 
SUPRACLAVICULAR APPROACH TO BRACHIAL PLEXUS 
SUBCLAVIAN PERIVASCULAR APPROACH 
Anatomical Land marks: The three trunks are clustered vertically over  
first rib cephaloposterior to subclavian artery. The neurovascular bundle lies 
inferior to  clavicle above its mid point. 
PROCEDURE:Patient is placed in a supine position with  head turned to the 
opposite side from the side to be blocked. The upper limb is pushed down to 
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depress the clavicle. The posterior border of the sternocleidomastoid is felt by 
asking the patient to raise the head while keeping his  head turned to the 
opposite side. The interscalene groove is  located behind the middle point of 
posterior border of the muscle. The anterior and middle scalene muscle can 
be made prominent by asking the patient to inhale vigorously. At 1 cm above 
the midpoint of the clavicle, Subclavian artery pulse can be felt in the 
interscalene groove. Stand to the side of the patient. On the right side 
interscalene groove is palpated with  left index finger and needle is inserted 
with right hand. After aseptic precautions and intradermal weal with local 
anaesthetics, a short bevelled 4 cm needle is inserted in the marked point. The 
Subclavian artery is guarded with thumb, needle is directed caudally, 
posteriorly and slightly medially. Needle enters the fascial sheath 1–2 cm 
deep to the skin approximately. Nerve block was performed by using a nerve 
stimulator (stimulation frequency was 2 Hz) ,stimulation intensity was 
decreased to less than or equal to 0.5MA after each muscular twitch; the 
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anesthetic volume was equally divided among arm flexion, as on exertion, 
wrist flexion and thumb adduction). The needle is held firmly and then local 
anaesthetic solution is injected after careful aspiration to exclude 
intravascular placement. Digital pressure proximal to needle insertion point 
may help to encourage distal spread.  
Complications : 1. Intravascular injection  
2. Pneumothorax 
3.Nerve injury 
 
 
 
 
 
 
 
  
20 
PHARMACOLOGY OF BUPIVACAINE(5,6,7,8) 
INTRODUCTION : 
       Bupivacaine is one of the homologous series synthesized  by 
A.F.Ekenstam in 1957.   
          Bupivacaine hydrochloride is 2-Piperidinecarboxamide,1-butyl-N-(2,6-
dimethylphenyl)-, monohydrochloride, monohydrate, a white crystalline 
powder that is freely soluble in  water,95 percent ethanol and slightly soluble 
in chloroform or acetone. First report of its use was made in 1963 by Telivuo. 
Bupivacaine is 3 to 4 times as potent as lignocaine. 
 
STRUCTURE: 
 
PROPERTIES : 
       Bupivacaine is  pharmacologically and chemically related to the 
aminoacyl local anesthetics. It is a homologue of mepivacaine and is 
chemically related to lidocaine.  
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All the 3 of these anaesthetics contain an amide linkage between the 
aromatic nucleus and  amino or piperidine group. They differ in this respect 
from procaine-type local anesthetics, which have an ester linkage. 
Bupivacaine hydrochloride, an amide is readily soluble in water and 
has good stability. The pH of plain solution is 6.0 to 6.7. Molecular 
weight is 324.9. It can be stored at room temperature. It is compatible 
with adrenaline and can be autoclaved more than twice. Commercially 
available bupivacaine contains no preservative. The chemical name of 
bupivacaine is (DL)-1-Butyl-2-(2,6-xylocarbonyl)-piperidine.It is 3 to 4 
times as potent as lignocaine.It crosses the blood brain barrier. 
1.Molecular weight base   288 
2.Pka     8.1 
3.Partition coefficient  346 
4.Mean uptake ratio  3.3 
5.Protein binding   96% 
MODE OF ACTION : 
 It causes reversible blockade of sodium conduction probably by dual 
actions on cell membrane.  
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Local anaesthetics block generation and conduction of nerve impulses, 
presumably by increasing threshold for electrical excitation in the nerve, by 
slowing the propagation of the nerve impulse, and by reducing the rate of rise 
in action potential. In general, the quality of the anesthesia is related to 
diameter, myelination, and the conduction velocity of affected nerve fibers.  
The order of loss of nerve function is as follows: 
(1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal 
muscle tone. 
PHARMACOLOGICAL EFFECTS : 
The effects produced by bupivacaine may be : 
(1) Local : 
Nerve blockade and a direct effect on smooth muscle. 
(2) Regional : 
Loss of pain and temperature sensations, touch, motor power and 
vasomotor tone in the region supplied by the nerve blocked. 
(3) Systemic :  
The main systemic effects are  (a)Cardiovascular system : 
Gross overdose is associated with ventricular fibrillation, 
ventricular  tachycardia and cardiac arrest.  
  
23 
 
However cardiac toxicity  occurs in subconvulsive doses or in 
respiratory or metabolic acidosis or in severe electrolyte disturbances.  
      With a dose of 1.2 mg/kg given intravenously at a rate of 4.3 mg/min, 
there is no change in pulse rate, ECG, blood pressure and cardiac output. It 
causes vasodilatation in the  areas supplied by the sympathetic nerves 
which are blocked. 
(b)Central nervous system : 
It produces sedation and light headedness; at times anxiety and 
restlessness. With marked toxicity, patient may notice a numb tongue, 
circumoral pin and needles, twitching and visual disturbances. Increased 
toxicity proceeds to convulsions and coma with respiratory and 
cardiovascular depression.\ 
(c)Autonomic nervous system : 
A weak blocking action on cholinergic and adrenergic  
receptors. 
(d)Neuromuscular junction : 
It can block motor nerves,when  present in sufficient concentration. 
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(e)Hypersensitivity : 
It can occur but more frequently in atopic patients in  form of local 
oedema, initially generalized urticaria or angioneurotic oedema with or 
without lymphadenopathy. Dermatitis may be encountered as delayed 
reaction, but anaphylaxis is very rare. 
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PHARMACOKINETICS:9 
 
Volume of distribution at steady state : 72 litres 
Terminal elimination half life  :210 minutes 
Clearance     :0.47litres/minute 
Metabolism :Liver by dealkylation to                 
pipecolyloxilidine 
Excretion     :5% by the kidney as unchanged drug 
                                                               and rest as metabolite. 
Absorption & Distribution: 
 
Vascularity of the tissue affects absorption of local anaesthetics. 
Bupivacaine has a great affinity for the negatively charged protein 
receptor sites. At a plasma concentration of 1 mcg/ml, the degree of 
protein binding is about 96.8% as opposed to 75% of lignocaine. 
Pharmacokinetic studies on plasma profile of Bupivacaine, after direct 
intravenous injection suggest a three-compartment open model.  
• The first compartment is represented by rapid intravascular 
distribution of the drug.  
• The second compartment represents equilibration of the drug 
throughout highly perfused organs such as myocardium, 
brain, lungs, kidneys & liver.  
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• The third compartment represents an equilibration of the drug 
with the poorly perfused tissues, such as muscle and fat.  
The elimination of the drug from tissues  depend largely upon the ability of 
binding sites in the circulation to carry it to the liver, where it is 
metabolized. 
Blood level :  
4 mcg/ml in plasma may cause convulsion. The peak plasma 
concentration appear slowly and reaches highest between 5-30 minutes. 
After reaching this level it falls slowly, this explains the longer duration of 
action. 
Factors affecting action: 
1.the presence of hepatic or renal disease 
2.addition of epinephrine 
3.factors affecting urinary pH, renal blood flow 
4.the route of drug administration 
5.the age of the patient.  
The half-life of Bupivacaine in adults is 2.7 hours and in neonates 8.1 
hours. 
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Placental transfer : 
As bupivacaine is highly protein bound, it passes to the fetus in a 
slower rate.It is not likely to cause fetal plasma concentration equal to that 
of maternal. Neonatal depression is not found with bupivacaine. 
Metabolism : 
It is rapidly catabolised like the other local anaesthetics and is  
mainly metabolised in the liver, demethylation of piperidene ring and 
coupling of glucuronic acid and  N-dealkylation to pipecolyxylidine 
(PPX) which is then hydrolysed. It has a fairly rapid rate of elimination 
from blood, because of the faster tissue uptake and rapid rate of 
metabolism and hence there is hardly any  accumulation of drug in the 
body, even after prolonged administration. Clinically found blood levels 
are much below the toxic dose. 
Excretion : 
Bupivacaine  is excreted through the  bile duct and kidney.  
The kidney is the main excretory organ for local anesthetics and their 
metabolites. Urinary excretion is affected by renal perfusion and factors 
affecting urinary pH. Only 6% of Bupivacaine is excreted unchanged in 
urine. 
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Uses : 
 
The uses are : 
(1) Local infiltration anaesthesia 0.25% 
(2) Nerve blocks 0.25% and 0.5% 
(3) Spinal anaesthesia 0.5% 
(4) Epidural analgesia : labour and post-operative analgesia 0.25% 
and 0.5% 
(5) Intravenous regional anaesthesia (IVRA) 
Doses:(10,11) 
It is available in 0.5% 20 ml vial,4 ml ampoule and 2 ml 1% ampoule. 
 Safe dose is 2 mg/kg of the body weight. Wide field block and 
surface application of  bupivacaine causes toxic reaction. 
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PHARMACOLOGY OF CLONIDINE 
Introduction: 
 Clonidine hydrochloride is a centrally acting selective partial alpha – 2 
agonist introduced in early 1960s. 
 Clonidine hydrochloride is an imidazoline compound and exists in a 
mesomeric form.The structural formula is C9H9C12N3HCI.  The chemical name 
is 2-(2,6–dichlorophenylamino)-2 imidazoline hydrochloride.. 
 The molecular weight is 266.56. Clonidine is an odourless, bitter, white, 
crystalline substance, soluble in alcohol and water. Clonidine improves quality of 
anaesthesia, provides more cardiovascular stability during anaesthesia, presumably 
because of its sympatholytic effect. Clonidine potentiates  anaesthetic action of the 
local anaesthetics with fewer side effects in peripheral nerve blocks and central 
neuraxial blockade.. Clonidine may reduce the halothane MAC by upto 50% in a 
dose dependent manner. 
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       CLONIDINE HYDROCHLORIDE 
 
Availability : 
 Available as one ml ampoule containing 150 micrograms. It should be stored 
below 25 degree Celsius. 
 
Mechanism of action:12 
 Clonidine is a centrally acting partial α2 adrenergic agonist with a selectivity 
ratio of 220: 1 for α2 receptors. The 3 subtypes of α2 receptors are α2a,α2b,α2c. 
α2a receptors mediate sedation, analgesia, sympatholysis.  
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α2b receptors mediate vasoconstriction and anti- shivering. The startle response 
may reflect the activation of α2c receptors. The drug is lipid soluble, penetrates  
blood brain barrier to reach the hypothalamus and medulla, when injected 
epidurally. It stimulates the inhibitory α2 adrenoreceptors and reduce central neural 
transmission in spinal neurons. The analgesic effect is caused by inhibition of 
substance-P. 
 The α2 adrenoreceptors are located on afferent terminals of both peripheral 
and spinal neurons in the superficial laminae of the spinal cord and within several 
brain stem nuclei involved in analgesia. The superficial laminae contain three 
groups of neurons: tonic, adapting, single- spike firing, all of which receive their 
primary sensory input from Aδ and C fibres.The ability of clonidine to modify the 
function of potassium channels in the CNS (Cell membrane become 
hyperpolarized) may be the mechanism for profound decrease in anaesthetic 
requirements. Clonidine inhibits voltage gated Na + and K+ channels and 
suppresses the generation of action potentials in tonic- firing spinal dorsal horn 
neurons, contributing to analgesic effect.  
There have been four proposed mechanisms for the action of clonidine in 
peripheral nerve blocks. These mechanisms are centrally mediated analgesia. 
α2adrenoceptormediated  vaso-constrictive effects, attenuation of inflammatory 
response and direct action on peripheral nerve. 
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 Another contribution to analgesic effect may be through the release of 
acetylcholine in the neuraxial region. α2adrenergic agonists also enhance analgesia 
from intraspinal opioids. Sedation is produced by its action on locus ceruleus. 
  In the periphery, it acts on pre-synaptic α2 adrenoreceptors at sympathetic 
terminals , reduces the release of nor-epinephrine, causing vaso-relaxation and 
reduced chronotropic drive. The brainstem and peripheral effects of α2 
adrenoreceptor stimulation are counter balanced by the direct peripheral 
vasoconstriction through its action on α2 adrenoreceptors from the circulating 
concentrations of clonidine. 
 Sedation is a desired property. Clonidine produces a dose dependent 
sedation at the dose of 50 micrograms or more in less than 20 minutes regardless of 
the route of administration. 
 Clonidine doesn’t induce profound respiratory depression even after massive 
overdose nor do they potentiate respiratory depression of opioids. 
 In peripheral nerves, it produces a little  blockade at high concentrations 
with some preference for C- fibres in the peripheral nerves and this effect in part 
enhance the peripheral nerve block, when added to local anaesthetics, probably 
because the α2 adrenoreceptors are absent in the axons of peripheral nerves. 
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Pharmacokinetics:(13,14,15,16) 
 Clonidine is well absorbed orally .It is nearly 100% bio-available, reaches 
peak plasma concentration with in 60 to 90 minutes. The mean half life of the drug 
in plasma is about 9 to 12 hours. Approximately 50% is  metabolized in the liver 
whereas  it is excreted in an unchanged form by the kidney, and its half- life can 
dramatically increase in the presence of impaired kidney function. 
 A transdermal delivery system is available  in which the drug is released at a 
constant rate for  a week. Three or four days are required to achieve a steady state 
concentration. 
  Clonidine is highly lipid soluble and readily distribute into  extra-vascular 
sites including the central nervous system. 
300 micrograms intravenously over 10 min produces: 
Distribution t ½ :  11 ± 9 minutes 
Plasma t ½ :    8 -12 hrs 
Elimination t ½ :  9 ± 2 hours, 41hours in severe renal failure. 
Volume of distribution :  2.1± 0.4 l/kg 
Plasma protein binding :  20 - 40% in vitro 
Plasma clearance :    12.6 L/hr/70 kg 
Metabolism :  minor pathways with the major metabolite,  
                                                 P – hydroxyclonidine. 
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Excretion: 
70% of the dose is excreted in the form of unchanged parent drug (40 – 
60%) in the urine. So, the elimination t ½ of clonidine varies as a function of 
creatinine clearance. In subjects undergoing hemodialysis, only 5% of the 
body clonidine  was removed. 
Precautions: 
In patients with renal failure, lower dose is needed. Sudden withdrawal of 
prolonged continuous epidural infusion produces a hypertensive crisis. 
Hence used with caution in patients with cerebrovascular or coronary 
insufficiency.If a patient with beta blocker is on continuous epidural therapy, 
beta blocker should be withdrawn several days before discontinuation of 
epidural clonidine. 
Contraindications: 
1. Known hypersensitivity to clonidine or its components. 
2. In patients with bradyarrhythmia or AV block 
3. Patients with severe cardiovascular disease 
4. Patients with cardiovascular and hemodynamic instability. 
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Interactions: 
1. Clonidine may potentiate the CNS depressive effect of alcohol, barbiturates 
or other sedative drugs. 
2. Narcotics may potentiate the hypotensive effects of clonidine. 
                                                                                                                                                                                                                                                                          
3. Tricyclic anti-depressants may antagonize the hypotensive effects of 
clonidine. 
4. Concomitant administration of drugs with a negative chronotropic 
dromotropic effect (beta blocker, digoxin) can cause or potentiate 
bradycardiac  rhythm disturbances. 
5. Beta blockers may potentiate hypertensive response seen with clonidine 
withdrawal. 
6. Epidural clonidine may prolong the duration of pharmacologic effects of 
epidural local anaesthetics, opioids, neostigmine and other drugs. 
 
Clonidine readily crosses placental barrier and may lower the foetal heart 
rate.Use of clonidine as an analgesic during labor and delivery is not indicated 
because maternal perfusion of the placenta is critically dependant on the blood 
pressure. 
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    In human breast milk, clonidine concentration are approximately twice that of 
maternal plasma.So it is contra indicated in lactating women. 
 
Uses :16 
• Pre-anaesthetic medication 
• Decrease anaesthetic requirements for inhaled and  injected anaesthetics. 
• Clonidine also attenuates  rise in intraocular pressure associated with 
laryngoscopy and intubation 
• Epidural block 
• Spinal anaesthesia 
• Caudal anaesthesia 
• Peripheral nerve blocks : Clonidine prolongs  duration of anaesthesia and 
analgesia with local anaesthetics by 2  times in a dose of 75 to 150 micro 
grams. 
•  Bier’s Block : 150 microgram of clonidine enhances the tourniquet 
tolerance 
•  It is also used in intra-articular analgesia 
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• Protection against perioperative myocardial ischemia; clonidine decreases 
myocardial ischemia, infarction and mortality following cardiovascular 
surgery. 
• To treat hypertensive crisis 
• Diagnosis of pheochromocytoma 
• Treatment of shivering 
• Treatment for opioid and alcohol withdrawal syndrome. 
 
Side effects; 
1. The most common side effects are sedation and xerostomia 
2. Cardiovascular complications are bradycardia, hypotension, and ECG 
abnormalities like sinusnode arrest, junctional bradycardia; high degree AV 
block and arrhythmia are reported rarely. Occasionally require treatment for 
bradycardia with I.V anticholinergics. Orthostatic hypotension occurs rarely. 
3. Rebound hypertension; Abrupt discontinuation of clonidine can result in 
rebound hypertension as soon as 8 hours and as late as 36 hours ,after the last 
dose.  
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Symptoms of nervousness, diaphoresis, headache, abdominal pain, and 
tachycardia often precede the actual increase in systemic blood pressure. 
Labetalol is useful in treatment of rebound hypertension. 
4. Skin rashes occur frequently. 
5. Impotence occurs occasionally. 
 
OVER DOSAGE: 
An overdosage of clonidine can produce vasospasm and hypertension. For 
hypertensive emergency,IV furosemide, diazoxide and alpha blocking agents may 
be used. There is no specific antidote for clonidine overdosage. Supportive 
measures like atropine, ephedrine, and i.v. fluids are enough.Yohimbine partially 
reverses the analgesia and sedation but not the BP and heart rate changes produced 
by epidural clonidine. 
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PHARMACOLOGY OF DEXMEDETOMIDINE 
 
Dexmedetomidine is a relatively selective alpha2-adrenoceptor agonist with 
 
Centrally mediated sympatholytic, sedative and analgesic effects. In general,  
 
dexmedetomidine has similar pharmacological effects to clonidine, which has been  
 
described as a useful and safe adjunct in many clinical applications. It  provides a  
 
unique “conscious sedation” (patients appear to be asleep, but are  readily roused), 
 
 analgesia, without respiratory depression. Dexmedetomidine  infusions  are used  
 
for sedation in  mechanically ventilated    patients. 
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STRUCTURE: 
 
 
 
MECHANISM OF ACTION OF DEXMEDETOMIDINE 
 
Alpha2 -receptors are found in  many sites  in  the  central  nervous  
 
system. However, the highest densities of alpha2-receptors are found in the 
 
locus  ceruleus .Presynaptic activation of the alpha2-A receptor in the locus 
 
ceruleus inhibits the release of norepinephrine and results in the  sedative and  
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hypnotic effects. In  addition, the locus ceruleus is the site of origin for the  
 
descending medullospinal noradrenergic pathway,known to be an important  
 
modulator of nociceptive neurotransmission. Stimulation in  this area  
 
terminates  the propagation of pain signals leading to analgesia.  Presynaptic 
 
activation of alpha2-adrenoceptorresults in decrease in sympathetic 
 
activity leading to hypotension and bradycardia.  Also, activation of  the 
 
alpha2- receptors   results in an augmentation of the cardiac vagal activity.  
 
When combined, these effects can produce analgesia, sedation and anxiolysis. 
 
At the spinal cord, stimulation of alpha2-receptors at the substantia 
 
gelatinosa of the dorsal horn leads to inhibition of the firing of nociceptive 
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neurons and inhibition of the release of substance P.  Also,  the alpha2- 
 
adrenoceptors located at the nerve endings have a possible role in the analgesic  
 
mechanisms by preventing nor-adrenaline release. The spinal mechanism  
 
is the principal mechanism for the analgesic action of dexmedetomidine even  
 
though there is a clear evidence for both supraspinal and peripheral sites of  
 
action. 
 
PHARMACOKINETICS 
Following intravenous administration, dexmedetomidine exhibits the following  
pharmacokinetic parameters: a rapid distribution phase with a distribution half-life   
of approximately 6 minutes; a terminal elimination half-life  of approximately 2  
hours; and a steady-state volume of distribution  of approximately 118 litres.  
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Clearance is estimated to be approximately 39 lit/hr and plasma protein binding is  
about 94%. 
METABOLISM AND ELIMINATION 
Dexmedetomidine undergoes almost complete biotransformation with  
 
minimal  unchanged dexmedetomidine excreted in urine and faeces. Hepatic  
 
metabolism involves both direct glucuronidation and oxidative metabolism.  
 
The major metabolic pathways of dexmedetomidine are  the direct N- 
 
glucuronidation  to inactive metabolites, aliphatic hydroxylation (mediated  
 
primarily by(CYP2A6)  and N-methylation.  Dexmedetomidine exhibits linear  
 
pharmacokinetics at therapeutic doses; the terminal elimination half-life is 
 
approximately 2 hours. About 95% of the total dose is recovered in the urine  
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and 4% in the feces by nine days following intravenous administration.No 
 
unchanged dexmedetomidine  is detected in the urine. 
 
SIDE EFFECTS 
 
Dexmedetomidine crosses the placenta and its safety is not established in  
pregnancy and in children. The common adverse  effects of dexmedetomidine  
include hypotension,  transient   hypertension, nausea, bradycardia, atrial  
fibrillation,  hypoxia  and   various atrioventricular blocks. Most of these adverse 
effects occur during the bolus dose of the drug. Omitting or reducing the loading 
dose can reduce the adverse effects. 
DOSAGE  
Dexmedetomidine prolongs the duration of anaesthesia and analgesia with 
local anaesthetics by two times in a dose of 1 µg/kg.” 
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REVIEW OF LITERATURE 
 “A study conducted by Dalle et al in 2001 explains the direct action of clonidine 
in nerve blockade. They proposed that clonidine, by enhancing the activity 
dependent hyperpolarisation generated by Na/K pump during repetitive 
stimulation, increases threshold for initiating the action potential causing slowing 
or blockage of conduction17. 
              A study conducted by Hutschala et al in 2004, by adding 100µg 
clonidine to bupivacaine 0.25%.It was found that adding the alpha 2 agonist 
clonidine to local anaesthetic agent bupivacaine enhances pain relief after 
peripheral nerve block.The lower plasma concentration of clonidine after 
peripheral nerve blockade strongly suggest a local effect.Administration of 
clonidine along with bupivacaine was associated with minimal sedation and a 
decrease in heart rate and stable blood pressure18. 
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Masuki et al in 2005,suggested that dexmedetomidine induces vasoconstriction 
via α2 adrenoceptors in the human forearm possibly also causing vasoconstriction 
around the site of injection,prolonging the effect of local anaesthetic by delaying 
its absorption.19 
Giovanni Cucchiaro and Arjunan Ganesh in 2007, evaluated effects of 
clonidine added to local anaesthetic bupivacaine for upper limb surgeries. Each 
group of 200 patients received either plain bupivacaine(LA) or bupivacaine with 
clonidine(LAC).Duration of sensory and motor blockade was significantly longer 
in LAC 1µg/kg group compared to LA group.They concluded that adding 
clonidine to bupivacaine prolonged the sensory and motor blockade20. 
  Yoshitomi et al in 2008,demonstrated that clonidine as well as 
dexmedetomidine enhanced the local anaesthetic action  of  lignocaine via 
peripheral  α2 A adrenoceptors.Other studies have shown that clonidine prolongs 
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the duration of anaesthesia and analgesia in brachial plexus block when added to 
bupivacaine21 
              A study by Brumett et al in 2008, showed that dexmedetomidine 
enhances the duration of bupivacaine anaesthesia and analgesia of sciatic nerve 
block in rats, without any damage to the nerve. The histopathological evaluation of 
these nerve axons and myelin were normal in both control and dexmedetomidine 
with bupivacaine groups22. 
             In an another study, perineural dexmedetomidine added to ropivacaine for 
sciatic nerve block in rats, prolonged the duration of analgesia, by blocking the 
hyperpolarisation-activatedcation. This effect was reversed by a hyperpolarisation 
activated cation channel enhancer,but not by an α2 adrenoreceptor antagonist. This 
shows that  analgesic effect of peripheral perineural dexmedetomidine was caused 
by  the enhancement of  hyperpolarisation-activated cation current, which prevents 
the nerve from returning from a hyperpolarized state to resting state23. 
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Popping et al. in 2009 in their metaanalysis of randomized trials, showed 
that  beneficial effect of clonidine on duration of analgesia was observed with all 
the tested local anaesthetics. They observed that  prolongation of motor block was 
higher, when clonidine was added to bupivacaine as compared with ropivacaine. 
The least effect was noted with prilocaine24. 
Kousugi et al. in 2010examined effects of various adrenoceptor agonists 
including dexmedetomidine, tetracaine, oxymetazoline and clonidine and also an 
α2 adrenoceptor antagonist (atipamezole) on compound action potential (CAP) 
recorded from frog sciatic nerve, and found that CAPs were inhibited by α2 
adrenoceptor agents so that they are able to block nerve conduction25. 
Dexmedetomidine and clonidine are both α2 selective agonists. It is 
possible that they work in a similar manner and may indicate a class effect. 
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Kosugi et al. in their study found that high concentrations of 
dexmedetomidine inhibit CAPs in frog sciatic nerves without 2 adrenoceptor 
activation. Their result showed that dexmedetomidinereduced peak amplitude of 
CAPs reversibly and in a concentration- dependent manner. This action was not 
antagonized by α2 adrenoceptor antagonists (i.e.,yohimbine and atipamezole).      
In fact,α2 antagonists reduced the CAP peak amplitude. Clonidine and 
oxymetazoline, two other α2 agonists, also inhibit CAPs. The maximum effect of 
clonidine was only 20%. 
Studies by Brummett and Kosugi showed that adrenaline, noradrenaline 
and α1 agonist phenylephrine \ and beta agonist isoprenaline had no effect on 
CAPs. The efficacy of peripheral perineural dexmedetomidine added to 
bupivacaine and ropivacaine for sciatic nerve blocks has been established(22, 23).The 
increase in duration of analgesia is dose dependent21 and the effect is peripheral 
(i.e., not caused by centrally mediated or systemic analgesia) 
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                Esmaoglu et al in 2010, have done  human studies on  greater palatine 
and axillary brachial plexus nerve blocks have subsequently demonstrated that 
increased duration of sensory blockade can be achieved by adding 
dexmedetomidine to bupivacaine and levobupivacaine, respectively26. Keeping 
these facts in mind, we decided to compare the action of two α2 agonists, i.e. 
clonidine and dexmedetomidine with bupivacaine in lesser concentration (0.25%), 
in peripheral nerve blocks so that by increasing the duration of analgesia with a 
single shot block, we can achieve a longer duration of post-operative analgesia 
without significant. 
Singelyn et al. reported that a minimum dose of clonidine (0.5 µg/kg) added 
to mepivacaine prolongs the duration of anaesthesia and analgesia after brachial 
plexus block. No added benefits were found with doses exceeding 1.5 µg/kg. The 
enhancing effect of a small dose of clonidine on lignocaine may be because of the 
evoked inhibition of C-fiber action potential.  
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Therefore, we decided to use clonidine at a dose of 1 µg/kg in our study28. 
Although dexmedetomidine has a α2/α1 selectivity ratio that is eight-times higher 
than that of clonidine, an equipotent comparative study of both the drugs in 
peripheral nerve block was not available at the time of our study. 
Rachana Gandhi et al in 2012,conducted a study to compare the  
 
postoperative analgesic efficacy and safety of dexmedetomidine for brachial plexus 
 
 blockade along with bupivacaine.They  used dexmedetomidine in the dose of  
 
30 µg in 2 ml added  38 ml of 0.25% bupivacaine.They concluded that  
  
Dexmedetomidine prolonged the duration of sensory and motor blockade36. 
 
Swami SS et al in 2012 have compared the efficacy of clonidine and 
dexmedetomidine as an adjuvant to bupivacaine in supraclavicular brachial plexus 
block.However the dose they have used for clonidine and dexmedetomidine was 
1µg/kg  each.They concluded that dexmedetomidine prolongs the duration of 
sensory and motor block and enhances the quality of block as compared with 
clonidine32. 
Amany S.Ammar et al  in 2012 studied the effect  of adding 
dexmedetomidine to bupivacaine  in infraclavicular brachial plexus block. The 
dose of dexmedetomidine added to 38 ml of 0.25 % of bupivacaine was 1µg/kg29. 
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They concluded that adding dexmedetomidine as an adjuvant prolonged  the 
duration of sensory and  motor blockade. 
 
Rao et al in 2014 have compared the efficacy of clonidine and 
dexmedetomidine as an adjuvant to bupivacaine in supraclavicular brachial plexus 
block in a dose of 1 µg/kg (in 2ml) added to 38 ml of 0.25% bupivacaine. 
Dexmedetomidine is more effective than clonidine when added to bupivacaine in 
supraclavicular brachialplexus block as it reduces onset of block and causes greater 
prolongation of both sensory and motor block33. 
Sandhya Agarwal et al in 2014,compared the effect of adding 
dexmedetomidine to bupivacaine in supraclavicular brachial plexus block for upper 
limb surgeries. They added 1µg/kg of dexmedetomidine to 38ml of 0.25% 
bupivacaine35. They concluded that  dexmedetomidine when added to bupivacaine 
for supraclavicular brachial plexus block shortens the onset times for sensory and 
motor blocks and prolongs their duration. The significantly prolonged duration of 
analgesia obviates the need for any additional analgesics. The added advantage of 
conscious sedation, hemodynamic stability, and minimal side effects makes it a 
potential adjuvant for nerve blocks. Patients in dexmedetomidine group were 
adequately sedated (modified Ramsay Sedation Score, RSS = 2/6 or 3/6)  
with no adverse effects except bradycardia in one patient. 
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Kenan Kaygusuz et al in 2012,studied  effects of adding Dexmedetomidine 
 
to Levobupivacaine in Axillary Brachial Plexus Block. They added 1µg/ml of  
 
dexmedetomidine to 39 ml of 5% bupivacaine.They concluded that adding  
 
dexmedetomidine to axillary brachial plexus block shortens onset  
 
time of sensory block, increases the duration of sensory and  motor blockade. 
 
 Harshavardhana H S et al  in  2014,conducted  a study to Efficacy of  
Dexmedetomidine compared to Clonidine added  to Ropivacaine  in 
Supraclavicular Nerve Blocks. They added 1µg/kg of either clonidine or 
dexmedetomidine to 38 ml of 0.25% bupivacaine. They concluded that 
Dexmedetomidine when added  to ropivacaine for brachial plexus block is a better 
adjuvant compared to clonidine30.  
  Saurabh Singh et al in 2014,conducted a study to compare the  
 
duration of sensory & motor blockade between clonidine & dexmedetomidine as  
 
adjuvants to 0.25% bupivacaine and  to  compare the hemodynamic parameters i.e.  
 
Heart rate, systolic blood pressure & diastolic blood pressure between  the  
 
clonidine and dexmedetomidine groups. They added 1µg/kg of either clonidine or  
 
dexmedetomidine to 38 ml of 0.25% bupivacaine. They  concluded  that   
 
Dexmedetomidine significantly prolonged the duration of action and significant  
 
decrease in haemodynamic parameters, but did not require any active  
 
intervention31.” 
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MATERIALS AND METHODS 
This study was carried out in the orthopaedic and plastic surgery theatre of 
Thanjavur Medical college,Thanjavur. 
         A prospective double blinded randomized controlled study was conducted on 
60 ASA I and II  patients undergoing upper limb surgeries under supra clavicular 
brachial plexus block who fulfill inclusion criteria. 
         This study was started after getting institutional ethical committee approval 
and informed written consent from all the patients undergoing the study.They were 
randomly divided into 2 groups namely group C and group D 
    Group C (Bupivacaine + clonidine) – 30 patients received 38 ml of 0.25% 
Bupivacaine and 100 micrograms of clonidine 
Group D (Bupivacaine + dexmedetomidine) – 30 patients received 38 ml of 
0.25%  bupivacaine and 100 micrograms of dexmedetomidine. 
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INCLUSION CRITERIA 
The following criteria were taken for including the patients in this study 
a) ASA status I and II 
b) Age between 16 and 60 
c) Weight between 40 and 70 kg 
d) Surgeries of moderate duration (60 to 90 minutes) 
e) Surgeries on distal end of arm ,forearm and hand 
EXCLUSION CRITERIA  
a) Patient refusal  
b) Known allergy for the drugs to be studied 
c) Local infections / sepsis 
d) Coagulation abnormalities 
e) Alcohol / drug abuse 
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f) Pregnant and lactating women 
g) Patient receiving chronic analgesic therapy 
h) Patients with severe cardiopulmonary disease, thyroid disorders,diabetes 
mellitus and central or peripheral neuropathies 
i) Other contraindications to regional anaesthesia 
MATERIALS 
1.sterile tray,sterile swab, sterile towel, sponge holding forceps 
2. drugs for the block  
   0.25% bupivacaine 
   Inj.clonidine 
   Inj.dexmedetomidine 
3.Nerve stimulator with insulated needle 
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4.Equipments and drugs for resuscitation and conversion to general anaesthesia in 
case of block failure. 
METHODS: 
PRE-OPERATIVE PREPARATION: 
Patients were preoperatively assessed and the procedure was explained to 
the patient . Written informed consent of all the patients under study was taken. 
Basic investigations recommended for ASA physical status I and II patients like 
hemoglobin, random blood sugar , blood urea, serum creatinine, urine for albumin 
and sugar and electrocardiogram were reviewed. 
All the patients were premedicated with Inj.Ranitidine 50 mg and Inj. 
Ondensetron 8 mg prior to the surgery. On arrival of patients to the operating room 
monitors like  pulse oximeter , non invasive blood pressure and ECG were 
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connected. Baseline values were  recorded. An 18G intravenous cannula was 
inserted in the contralateral forearm and an IV infusion started. 
SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK 
Anatomical Land marks: The three trunks are clustered vertically over first 
rib cephaloposterior to subclavian artery. The neurovascular bundle lies inferior to  
clavicle above its mid point. 
PROCEDURE:Patient were positioned supine with  head turned to the opposite 
side from the side to be blocked. The upper limb was pushed down to depress the 
clavicle. The posterior border of the sternocleidomastoid was felt by asking him to 
raise the head while keeping his  head turned to the opposite side. The interscalene 
groove should be located behind the middle point of posterior border of the 
muscle. The anterior and middle scalene muscle can be made prominent by asking 
the patient to inhale vigorously. At 1 cm above the midpoint of the clavicle,  
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Subclavian artery pulsation can be felt in the interscalene groove. Stand to the side 
of the patient. On the right side, interscalene groove is palpated with  left index 
finger and needle is inserted with right hand. After aseptic precautions and 
intradermal weal with local anaesthetics, a short bevelled 4 cm needle is inserted in 
the marked point. The Subclavian artery is guarded with thumb, needle is directed 
caudally, posteriorly and slightly medially. Needle enters the fascial sheath 1–2 cm 
deep to the skin approximately. Nerve block were performed by using a nerve 
stimulator          (stimulation frequency was 2 Hz ,stimulation intensity was 
decreased to less than or equal to 0.5MA after each muscular twitch; the anesthetic 
volume was equally divided among arm flexion, wrist flexion and thumb 
adduction). The needle is held firmly and then local anaesthetic solution is injected 
after careful aspiration to exclude intravascular placement. Digital pressure 
proximal to needle insertion point may help to encourage distal spread.  
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 In the absence of a desired response, the needle was redirected cephalad or 
caudad, but never medially to avoid the pleura. When these manoeuvers failed to 
result in desired motor response the needle was withdrawn and the landmarks were 
reassessed and tried again. 
EVALUATION OF THE BLOCK: 
Evaluation of degree of blockade was done by Hollmen’s scale 
HOLLMEN’S SCALE 
SENSORY BLOCKADE: 
1.Normal sensation of pin prick 
2.Pin prick felt as sharp pointed but weaker compared with the same area with the 
other limb 
3.Pin prick recognized as touch with blunt object 
4.No perception of pin prick 
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MOTOR BLOCKADE: 
1.Normal muscle function. 
2.Slight weakness in muscle function 
3.Very weak muscular action 
4. Complete loss of muscle function 
• Following the administration of the drug , the patients were evaluated for 
onset of sensory and motor blockade every minute 
• Onset of sensory block: The time interval between administration of drug 
and absence of sensation to pin prick (Hollmen’s ≥3). 
• Onset of motor blockade: Time interval between administration of the drug 
and complete loss of muscle function(Hollmen’s ≥3) Motor block was 
assessed by wrist flexion and extension or finger flexion and extension .Only 
patients with complete motor block was included in this study. 
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• Duration of sensory blockade:Time interval between onset of complete 
sensory block and the onset of pain in the post operative period 
• Duration of motor blockade :Time interval between onset of complete 
motor block and the recovery of normal muscle power 
• Failed block was managed with general anaesthesia. Those patients are 
excluded from the study. 
• After conformation that the block has taken up , surgery was started. 
• Patient received supplemental O2 and intravenous fluids throughout the 
procedure. 
• Sedation was assessed using sedation scale described by Culebras for 24 
hours postoperatively(14) 
Group 1:Awake and alert 
Group 2: sedated , responding to verbal commands 
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Group 3: sedated , responding to mild physical stimulus 
Group 4: sedated, responds to moderate or severe physical stimulus 
Group 5: not arousable 
• Local anesthetic toxic reactions including subjective manifestations like 
circumoral numbness, tinnitus, twitching,convulsions,etc.,were looked for 
and appropriate resuscitative drugs were kept ready. 
• Complications associated with the technique like intravascular injection and 
pneumothorax were looked for and appropriate measures were taken to meet 
any such eventuality. 
• Heart rate , non invasive blood pressure, oxygen saturation and sedation 
scores were recorded at 0 min,5 min, 10 min, 15 min, 30 min, 60 min, 2 hrs, 
6 hrs, 12 hrs and 24  hrs 
• Inj. Diclofenac 75 mg intramuscularly was given as a rescue analgesic when 
the patient complains of pain in the postoperative period. 
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• Patients were observed for 24 hrs for the following side effects. 
a) Bradycardia; heart rate less than 60 beats / min 
b) Hypotension ; more than 30% decrease from base line value 
c) Shivering 
d)  Dry mouth 
e) Arrhythmias  
f) Local anaesthetic toxicity 
All the data were subjected to statistical analysis using Statistical Package for 
Social Sciences (SPSS), version 15. Duration of sensory and motor block, and 
haemodynamic parameters were subjected to Independent t-test for statistical 
analysis. P-value < 0.05 was considered as statistically significant and P < 0.001 as 
highly significant. 
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OBSERVATIONS AND RESULTS 
 
All the data were subjected to statistical analysis using Statistical Package 
for Social Sciences (SPSS), version 15. Duration of sensory and motor block, and 
haemodynamic parameters were subjected to Independent t-test for statistical 
analysis. P-value < 0.05 was considered as statistically significant and P < 0.001 as 
highly significant. 
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SEX DISTRIBUTION 
 
SEX C GROUP D GROUP TOTAL 
MALE 16 18 34 
FEMALE 14 12 26 
TOTAL 30 30 60 
 
Male to female ratio in group C was 53/47  
and in group D was 60/40, which were comparable 
 
 
Comparison of sex distribution between Group C(Clonidine with Bupivacaine) 
and Group D(Dexmedetomidine with Bupivacaine) 
 
SEX RATIO
MALE
FEMALE
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AGE DISTRIBUTION 
 
AGE C GROUP D GROUP  TOTAL ‘p’ value 
16 – 20 YRS 6 10 16  
 
0.308 
20 -29 YRS 9 7 16 
30-39 YRS 5 6 11 
40-49 YRS 7 4 11 
ABOVE 50 3 3 6 
TOTAL 30 30 60 
Mean 33.33±14.55 29.13±12.59   
 
Mean age in group C is 33.33±14.55 
Mean age in group D is 29.13±12.59 
These mean ages were comparable 
 
Comparison of age distribution between Group C(Clonidine with Bupivacaine) 
and Group D(Dexmedetomidine with Bupivacaine) 
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WEIGHT DISTRIBUTION 
 
Descriptive Statistics 
GROUP N Minimum Maximum Mean Std. 
Deviation 
C 
WEIGHT 30 35.00 65.00 47.8667 6.17410 
Valid N 
(listwise) 
30     
D 
WEIGHT 30 40.00 60.00 49.6667 4.43601 
Valid N 
(listwise) 
30     
 
 
 
     
 
Mean weight in group C was 47.86±6.17 
 
Mean weight in group D was 49.66±4.43 
 
These mean weights were comparable in both groups.  
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COMPARISON OF WEIGHT DISTRIBUTION BETWEEN GROUP C AND GROUP D 
 
 
 
 
Weight distribution as compared between Group C(Clonidine with Bupivacaine) 
 
and Group D(Dexmedetomidine with Bupivacaine) 
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COMPARISON OF HAEMODYNAMIC PARAMETERS AND SEDATION    
SCORE BETWEEN C AND D GROUPS 
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statistic Statistic Std. 
Error 
Statistic 
C 
  PULSE RATE 
30 79.2667 1.22703 6.72070 Pulse 
rate=0.166 
 
MEAN ARTERIAL 
PRESSURE 
30 75.1000 1.41369 7.74307 Mean 
pressure= 
0.095 
SATURATION 
30 99.1667 .06920 .37905 Saturation= 
0.139 
 
SEDATION SCORE 
30 1.0000 .00000 .00000 Sedation 
score= 
0.001 
Valid N (listwise) 30     
D 
PULSE RATE 30 79.2333 1.46506 8.02446  
MEAN ARTERIAL 
PRESSURE 
30 71.4333 .95615 5.23703  
SATURATION 30 99.0333 .05839 .31984  
SEDATION SCORE 30 2.0000 .00000 .00000  
Valid N (listwise) 30     
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COMPARISON OF PULSE RATE BETWEEN GROUP C AND D 
 
PULSE RATE 
GROUP N Mean Std. 
Deviation 
‘P’ 
Value 
Statistic Statistic Std. 
Error 
Statistic 
C 30 79.2667 1.22703 6.72070 
0.308 
D 30 79.2333 1.46506 8.02446 
 
The mean pulse rate in group C was 79.26±6.72  
 
The mean pulse rate in group D was 79.23±8.02  
 
These rates were statistically comparable 
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COMPARISON OF MEAN ARTERIAL PRESSURE BETWEEN GROUP C 
AND GROUP D 
 
MEAN ARTERIAL PRESSURE 
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statistic Statistic Std. 
Error 
Statistic 
C 30 75.1000 1.41369 7.74307 
0.095 
D 30 71.4333 .95615 5.23703 
 
 
The mean arterial pressure in group C was 75.100±7.74  
  
The mean arterial pressure in group D was 71.43±5.23 
 
These means were statistically comparable 
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COMPARISON OF OXYGEN SATURATION BETWEEN GROUP C AND 
GROUP D 
 
SATURATION 
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statistic Statistic Std. 
Error 
Statistic 
C 30 99.1667 .06920 .37905 
0.139 
D 30 99.0333 .05839 .31984 
 
 
The mean oxygen saturation in group C was 99.16±0.37 
  
The mean oxygen saturation in group D was 99.03±0.31 
 
These means were statistically comparable 
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COMPARISON OF SEDATION SCORE BETWEEN GROUP C AND 
GROUP D 
 
 
SEDATION SCORE 
GROUP N Mean Std. 
Deviation 
‘P’ 
Value 
Statistic Statistic Std. 
Error 
Statistic 
C 30 1.0000 .00000 .00000 
0.000 
D 30 2.0000 .00000 .00000 
 
 
The mean sedation score in group C was 1.00 
  
The mean sedation score in group D was 2.00 
 
These means were statistically significant. 
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COMPARISON OF ONSET OF ACTION OF SENSORY BLOCK 
 
 Onset of sensory blockade is the time interval between administration of 
drug and absence of sensation to pin prick (Hollmen’s ≥3). 
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ONSET OF ACTION OF SENSORY BLOCK IN GROUP 
D(DEXMEDETOMIDINE WITH BUPIVACAINE) 
 
The time interval between administration of dexmedetomidine with bupivacaine 
and absence of sensation to pin prick (Hollmen’s ≥3) is recorded in minutes as the 
onset of sensory block 
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Comparison of onset of action of sensory block in group C 
(clonidine with bupivacaine) and group D(dexmedetomidine 
with bupivacaine) 
  
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statistic Statistic Std. 
Error 
Statistic 
C 
ONSET OF 
SENSORY BLOCK 
30 2.8667 .14169 .77608  
Valid N (listwise) 30    0.14 
D 
ONSET OF 
SENSORY BLOCK 
30 2.5333 .18404 1.00801  
Valid N (listwise) 30     
. 
    This table shows that the onset time of sensory blockade in group D is lesser  
than that of group C.On statistical analysis, this difference was found to be  
insignificant 
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Mean duration of onset of action of sensory block in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) is  
 
drawn as follows: 
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COMPARISON OF ONSET OF ACTION OF MOTOR BLOCK 
 
  
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statisti
c 
Statisti
c 
Std. 
Error 
Statistic 
C 
ONSET OF 
MOTOR BLOCK 
30 5.6667 .25521 1.39786  
Valid N (listwise) 30    0.000 
D 
ONSET OF 
MOTOR BLOCK 
30 5.4667 .34486 1.88887  
Valid N (listwise) 30     
 
This table compares the onset of motor blockade in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine). 
 
This table shows that the onset time of sensory blockade in group D is lesser  
 
than that of group C. On statistical analysis, this difference was found to be  
 
significant 
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Onset of motor blockade in group C(clonidine with bupivacaine)  was the time 
 
interval between administration of drug and complete loss of muscle function  
 
(Hollmen’s ≥3) was plotted in minutes as follows: 
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Onset of motor blockade  groupD(dexmedetomidine with bupivacaine) was  
 
time interval between administration of drug and complete loss of muscle function 
 
(Hollmen’s ≥3) was plotted in minutes as follows: 
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MEAN OF ONSET OF ACTION OF MOTOR BLOCK  
 
Mean duration of onset of action of motor block in group C(clonidine with  
 
bupivacaine) was compared with group D(dexmedetomidine with bupivacaine)  as  
 
follows: 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
GROUP C GROUP D
MEAN OF ONSET OF ACTION OF MOTOR 
BLOCK
ONSET OF ACTION OF 
MOTOR BLOCK
 83 
 
 
COMPARISON OF DURATION OF ACTION OF SENSORY BLOCK 
IN GROUP C (CLONIDINE WITH BUPIVACAINE) AND GROUP 
D(DEXMEDETOMIDINE WITH BUPIVACAINE) 
 
 
Duration of sensory blockade recorded as time interval between onset of complete  
sensory block and the onset of pain in the post operative period in group C  
(clonidine with bupivacaine) 
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DURATION OF SENSORY BLOCK IN GROUP D 
Duration of sensory blockade recorded as time interval between onset of complete  
sensory block and the onset of pain in the post operative period in group  
D(dexmedetomidine with bupivacaine) 
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COMPARISON OF DURATION OF SENSORY BLOCKADE 
 
 
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statistic Statistic Std. 
Error 
Statistic 
C 
DURATION OF 
SENSORY BLOCK 
30 224.500
0 
5.97018 32.70005  
Valid N (listwise) 30    0.000 
D 
DURATION OF 
SENSORY BLOCK 
30 414.633
3 
12.8451
9 
70.35598  
Valid N (listwise) 30     
 
This table compares the duration of sensory blockade in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) . 
 
This table shows that the duration time of sensory blockade in group D is greater  
 
than that of group C. On statistical analysis, this difference was found to be  
 
significant 
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MEAN  DURATION OF SENSORY BLOCK 
 
Mean duration  of action of sensory block in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) is  
 
drawn as follows: 
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COMPARISON OF DURATION OF ACTION  OF MOTOR BLOCK 
 
Time interval between onset of complete motor block and the recovery of 
normal muscle power was recorded in group C(clonidine with bupivacaine) 
as follows: 
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DURATION OF MOTOR BLOCK IN GROUP D 
Time interval between onset of complete motor block and the recovery 
of normal muscle power was recorded in group D(dexmedetomidine
with bupivacaine) as follows: 
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COMPARISON OF DURATION OF ACTION OF MOTOR BLOCK IN 
GROUP C (CLONIDINE WITH BUPIVACAINE) AND GROUP 
D(DEXMEDETOMIDINE WITH BUPIVACAINE) 
 
GROUP N Mean Std. 
Deviation 
‘P’ 
value Statistic Statistic Std. Error Statistic 
C 
DURATION OF 
MOTOR BLOCK 
30 307.7000 6.37436 34.91383  
Valid N (listwise) 30    0.000 
D 
DURATION OF 
MOTOR BLOCK 
30 489.1667 13.29195 72.80303  
Valid N (listwise) 30     
 
This table compares the duration of motor  blockade in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) . 
 
This table shows that the duration time of motor  blockade in group D is greater  
 
than that of group C. On statistical analysis, this difference was found to be  
 
significant 
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MEAN DURATION  OF  MOTOR  BLOCK 
 
Mean duration  of action of motor  block in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) is  
 
drawn as follows: 
 
 
 
 
 
 
 
0
100
200
300
400
500
600
GROUP C GROUP D
MEAN OF DURATION OF MOTOR BLOCK
MEAN OF DURATION OF 
MOTOR BLOCK
 91 
 
DURATION OF RESCUE ANALGESIA 
Duration of rescue analgesia as recorded when the patient complains of pain 
in the postoperative period for the first time; plotted in group 
C(clonidine with bupivacaine) 
 
DURATION FOR RESCUE ANALGESIA IN GROUP C 
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DURATION OF RESCUE ANALGESIA IN GROUP D 
 
Duration of rescue analgesia as  recorded when the patient complains of pain  
in the postoperative period for the first time; plotted in group  
D(dexmedetomidine with bupivacaine) 
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COMPARISON OF DURATION FOR RESCUE ANALGESIA IN GROUP 
C(CLONIDINE WITH BUPIVACAINE) WITH GROUP D (DEXMEDETOMIDINE 
WITH BUPIVACAINE) 
Descriptive Statistics 
 
 
GROUP N Mean Std. 
Deviation 
‘P’ 
value 
Statistic Statistic Std. 
Error 
Statistic 
C 
DURATION OF 
RESCUE 
30 263.100
0 
7.40058 40.53466  
Valid N (listwise) 30    0.00 
D 
DURATION OF 
RESCUE 
30 455.966
7 
13.0262
8 
71.34785  
Valid N (listwise) 30     
 
This table compares the duration for rescue analgesia in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) . 
 
This table shows that the duration for rescue analgesia  in group D is greater  
 
than that of group C. On statistical analysis, this difference was found to be  
 
significant 
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MEAN DURATION FOR RESCUE ANALGESIA 
 
Mean duration for rescue analgesia in group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) drawn  
 
as follows: 
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SEDATION SCORE 
 
 
 
Sedation score as compared between group C(clonidine with  
 
bupivacaine) compared with group D(dexmedetomidine with bupivacaine) 
Mean sedation score in Group C was 1 
Mean sedation score in Group D was 2 
This difference was statistically significant.(P value < 0.005) 
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DISCUSSION 
The demonstration of α2 receptors in the peripheral nervous system  
prompted recent trials on the usage of α2 rece[ptor agonists,like clonidine 
and dexmedetomidine combined with bupivacaine for brachial plexus block 
for upper limb surgeries.Several studies have shown that addition of these 
adjuvants produce a longer duration of post operative analgesia.  
         The data was compiled and subjected to statistical analysis using 
Statistical Package for Social Sciences (SPSS), version 15. Duration of 
sensory and motor block, and haemodynamic parameters were subjected to 
Independent t-test for statistical analysis. P-value < 0.05 was considered as 
statistically significant and P < 0.001 as highly significant                   
 The  mean age(in years) of the patients in group C(clonidine with 
bupivacaine) was 33.33±14.55.The mean age of patients in group 
D(dexmedetomidine with bupivacaine) was 29.13±12.59. The mean age of 
both the groups were comparable. 
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Male to female in group C was 53/47 and in group D was 60/40, 
which were comparable. Duration of surgery in group C was 92.50±12.78 
and in group D was 95.16±11.48 both were demographically comparable. 
 
DOSAGE OF ALPHA AGONIST: 
 In the study of Eledjam JJ et al 28clonidine 150µg was added to 40 ml 
of 0.25% bupivacaine to find the efficacy of α2 agonist on brachial plexus block. 
Swamy et al added 1µg/kg of either clonidine or dexmedetomidine  to bupivacaine 
0.25% (35 cc) to compare their efficacy on supraclavicular brachial plexus  block 
study27. Rao et al added  1µg/kg of either clonidine or dexmedetomidine  to 
bupivacaine 0.25% (38 cc) to compare their efficacy on supraclavicular brachial 
plexus  block. Therefore we decided to use 1 µg/kg of clonidine or 
dexmedetomidine added  to 38 ml of 0.25% bupivacaine to compare their efficacy 
on brachial plexus block. 
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ONSET OF SENSORY BLOCK: 
  Onset of sensory block in group C was 2.86±0.77 minutes .Onset of 
sensory block in group D was 2.53±1.0 minutes. Onset of sensory block in group D 
is faster than group D but this difference was not statistically significant. This 
reduction in onset time of sensory blockade correlates with the study by Swamy et 
al(2012) and Rao et al(2014) 
ONSET OF MOTOR BLOCK: 
  Onset of motor   block in group C was 5.66 ±1.39 minutes .Onset of 
motor block in group D was 5.66±1.48 minutes. Onset of motor block in group D 
is faster than group D; this difference was statistically significant.  ‘p’ value < 
0.005.This reduction in onset time of motor blockade correlates with the study   
done by Swamy et al(2012)27, Rao et al(2014) , Saurabh Singh et al (2014) 
DURATION OF SENSORY BLOCKADE: 
  Duration of sensory blockade in group C was 224.50±32.70 
minutes.Duration of sensory blockade in group D was 414.63±70.35 minutes. 
Duration of sensory blockade in group D was statisitically significant when 
compared to group C. This corroborates with the study done by Swami et al (2012) 
(413.97±87.31) and Rao et al(2014) (400.15±85.13minutes)28 
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DURATION OF MOTOR BLOCKADE: 
  Duration of motor blockade in group C w  307.70±34.91 
minutes.Duration of motor  blockade in group D was 489.16±72.80 minutes. 
Duration of motor blockade in group D was statistically significant when compared 
to group C.This corroborates with the study done by Swami et al (2012) 
(472.24±90.06) and Rao et al(2014) (470±86 minutes) 
 
HAEMODYNAMIC PARAMETERS: 
  In this study, there was no significant change in the haemodynamic 
baseline in both the groups.This was consistent with the observation by Obayah 
et al(2010)25,Swami et al(2012)27and Rao et al(2014)28 
 
SIDE EFFECTS: 
  None of the patients in the two groups showed any side effects like 
bradycardia, hypotension, shivering,  dry mouth, arrhythmias and local anaesthetic 
toxicity. 
  In the study by Swami et al in 2012 none of the patients reported 
clonidine or dexmedetomidine related side effects when added to bupivacaine in 
supraclavicular brachial plexus blocks for upper limb surgeries. 
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 In another study by Rao et al in 201428, no significant side effects like 
hemodynamic instability and shivering were observed when clonidine or 
dexmedetomidine was added to bupivacaine in supraclavicular brachial plexus 
block for upper limb surgeries of moderate duration.This was consistent with the 
observation byPopping et al22and Esmaoglu et al24.Popping et al added clonidine as 
an adjuvant to bupivacaine in  supraclavicular brachial plexus blocks for upper 
limb surgeries.Similarly Esmaoglu et al added dexmedetomidine as an adjuvant to 
bupivacaine in  supraclavicular brachial plexus blocks for upper limb surgeries.No 
side effects were observed in both these studies. 
 
SEDATION SCORE: 
  The mean sedation score in group C(clonidine with bupivacaine) was 
1.0.The mean  sedation score in group D(dexmedetomidine with bupivacaine) was 
2.0. This difference in sedation score was statistically significant(‘p’ value< 
0.005).Sedation  is desired in the immediate  post operative period. In this regard 
dexmedetomidine produces better sedation than clonidine when added to 
bupivacaine in supraclavicular brachial plexus blocks for upper limb surgeries of 
moderate duration(60 to 90 minutes) 
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TIME FOR RESCUE ANALGESIA: 
 Duration of rescue analgesia as  recorded when the patient complains  
of pain in the postoperative period for the first time; plotted in group  
D(dexmedetomidine with bupivacaine) was 455.96 ± 71.34 minutes verses group  
C(clonidine with bupivacaine) was 263.1± 40 minutes. 
  In the study by Swamy et al(2012),Rao et al(2014) and Saurabh 
 Singh(2014) dexmedetomidine considerably prolonged the time for rescue 
 analgesia when compared to clonidine.This is consistent with our present study 
 where dexmedetomidine proves better than clonidine. 
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SUMMARY 
  We conducted this study at Thanjavur Medical Clooge Hospital in 60 
patients of both sexes in the age group of 16 -60 years belonging to ASA I and II 
and their weight ranging between 40-70 kg, posted for various upper limb surgeries 
under supraclavicular brachial plexus block.  
In clinical studies, adding clonidine or dexmedetomidine to local anaesthetic 
solutions improved peripheral nerve blocks by quickening the onset time, 
improving  the quality of block during surgery and extending  post operative 
analgesia. Clonidine and dexmedetomidine  possibly amplify  the Na+ channel 
blockade action of local anaesthetic by opening up the K+ channels resulting in 
membrane hyperpolarisation.  
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This study compares clonidine and dexmedetomidine as an adjuvant to 
bupivacaine for brachial plexus block by supraclavicular approach for 
orthopaedic procedures of moderate duration using nerve stimulator. On 
comparing  the efficacy of  adding Clonidine as an adjuvant  to Bupivacaine as 
compared to Dexmedetomidine as adjuvant to Bupivacaine in supraclavicular 
brachial plexus blocks for upper limb surgeries, it was found that 
dexmedetomidine 
• Accelerated the onset of  sensory and motor blockade. 
• Prolonged the duration of motor and sensory blockade. 
• Prolonged the time for rescue analgesia in the post-operative period. 
• Produced  mild to moderate sedation in the post-operative period 
• Did not cause any significant haemodynamic changes or adverse effects. 
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CONCLUSION 
  We conclude that addition of 1 µg/kg of dexmedetomidine to 0.25 % 
bupivacaine accelerates the onset of sensory and motor block, prolongs the 
duration of sensory and motor block and the time for rescue analgesia with mild 
sedation without any adverse effects,  when compared to clonidine as an adjuvant 
to bupivacaine in supraclavicular brachial plexus blocks for upper limb surgeries 
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GROUP C  (Bupivacaine + Clonidine) 
S. 
NO Name Age Sex Wt. 
PR 
(mean) 
BP 
(mean) 
Sat. 
(mean) 
Sens. 
ons. 
Mtr. 
ons. 
Drn. 
sens 
Drn. 
mtr. 
Drn. 
rescue 
Sedn. 
score 
1. Shanmugam 38 M 48 72 70 99 2 3 220 300 290 1 
2. Jeya 30 F 45 76 71 100 2 4 230 290 280 1 
3. Karupaiyan 45 M 49 71 72 99 2 3 230 310 290 1 
4. Sivanathan 38 M 49 78 81 99 2 6 210 310 220 1 
5. Dinesh 23 M 50 81 78 99 2 4 240 340 300 1 
6. Hemavathy 16 F 40 78 68 99 3 6 210 320 290 1 
7. Ranjithkumar 20 M 52 82 67 99 3 6 200 230 220 1 
8. Valarmathy 40 F 56 78 78 99 3 7 180 260 210 1 
9. Poominathan 19 M 50 76 81 100 2 5 250 340 310 1 
10. Chetlaswamy 18 M 42 82 82 99 3 6 260 350 290 1 
11. Vijendran 28 M 50 90 83 99 3 7 280 350 310 1 
12. Ananthi 20 F 52 77 91 99 2 4 248 298 252 1 
13. Vairakannu 65 F 48 74 101 99 3 7 256 322 272 1 
14. Muthulakshmi 45 F 47 82 78 99 3 5 248 348 370 1 
15. Sundramoorthy 46 M 49 79 82 99 3 6 247 347 280 1 
16. Desika 17 F 40 81 78 99 3 7 190 280 210 1 
17. Dharmaraj 28 M 52 78 68 99 3 6 192 280 230 1 
18. Manikandan 19 M 55 81 69 100 2 5 200 300 250 1 
19. Amaravathy 65 F 45 69 70 99 3 6 232 280 248 1 
20. Kannagi 25 F 65 79 71 99 2 4 178 260 212 1 
21. Priyanka 21 F 45 72 68 99 3 6 260 340 290 1 
22. Arivalagan 48 M 45 89 76 99 5 5 248 330 290 1 
23. Govindaraj 43 M 40 91 68 100 3 6 248 338 269 1 
24. Vaduvayee 47 F 35 89 78 99 4 7 200 280 240 1 
25. Rasiga 17 F 48 98 72 99 3 5 180 270 210 1 
26. Prakash 27 M 59 71 69 99 3 6 180 270 220 1 
27. Chellapappu 60 F 45 72 74 99 3 6 180 278 210 1 
28. Shalini 36 F 50 75 68 99 3 6 190 290 230 1 
29. Thamaraiselvan 22 M 40 71 69 99 3 6 278 360 300 1 
30. Ravikumar 34 M 45 71 72 100 5 10 270 360 300 1 
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GROUP D  (Bupivacaine +Dexmedetomidine) 
S.NO Name Age Sex Wt. PR (mean) 
BP 
(mean) 
Sat. 
 
Sens. 
ons. 
Mtr. 
ons. 
Drn. 
sens 
Drn. 
mtr. 
Drn. 
rescue 
Sed. 
score 
1. Hemalatha 16 F 52 78 65 99 2 6 320 400 360 2 
2. Azhaguraja 19 M 54 82 66 99 3 7 350 450 400 2 
3. Rameshkumar 40 M 48 81 67 99 1 3 460 500 480 2 
4. Saleem 24 M 50 76 76 99 3 6 480 540 310 2 
5. Murugesan 40 M 50 91 67 99 3 6 460 520 480 2 
6. Kishorekumar 17 M 48 89 68 99 3 6 485 550 500 2 
7. Manimegalai 48 F 45 78 69 99 2 3 320 350 340 2 
8. Vijayabalan 32 M 50 89 72 99 3 6 472 538 500 2 
9. Pakrudhin 21 M 54 72 71 99 3 6 482 541 520 2 
10. Ramadoss 58 M 50 71 69 99 2 4 480 540 510 2 
11. Santhosh 17 M 51 71 78 99 1 3 330 360 348 2 
12. Parasuraman 18 M 51 68 71 99 2 4 330 370 340 2 
13. Priyadharsini 17 F 50 89 66 99 3 6 472 530 512 2 
14. Kavitha 17 F 44 91 67 99 3 7 466 538 520 2 
15. Divya 16 F 46 78 68 99 2 4 360 394 378 2 
16. Perumal 35 M 52 82 69 99 1 2 400 500 450 2 
17. Palanisamy 16 M 42 88 70 100 3 5 478 538 520 2 
18. Gnanamary 35 F 50 77 69 99 2 6 470 530 500 2 
19. Manikandan 27 M 60 78 64 99 2 5 246 536 500 2 
20. Dharmaraj 28 M 48 68 72 99 2 4 420 520 500 2 
21. Alagudevi 24 F 52 69 71 100 3 6 440 590 480 2 
22. Chinnaponnu 51 F 55 72 78 99 2 8 450 538 510 2 
23. Saravanan 32 M 55 74 76 99 5 10 470 530 500 2 
24. Vijakumar 30 M 50 76 82 98 2 5 460 560 480 2 
25. Periyanayaki 55 F 40 78 81 99 5 10 326 396 375 2 
26. Kanniyammal 32 F 54 91 80 99 3 6 470 538 500 2 
27. Kasthuri 45 F 49 68 68 99 4 5 482 542 520 2 
28. Ilakkiya 21 F 40 72 67 99 3 5 330 396 556 2 
29. Sundaresan 26 M 52 89 76 99 1 3 330 360 350 2 
30. Muthusamy 17 M 48 91 80 99 2 7 400 480 440 2 
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            CONSENT FORM 
 
 
I __________________________________________  hereby give consent to 
participate in  the study conducted by DR.V.SARAVANAGOPI ,  post graduate 
in department of Anaesthesiology ,Thanjavur medical college & hospital, 
Thanjavur  and to use my personal clinical data and result of investigation for the 
purpose of analysis and to study the nature of disease. I also give consent for 
further investigations 
 
 
Place : 
Date :       Signature of participant 
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Annexure I 
Name  :    Age/Sex:   IP No: 
Hospital :    Date: 
Preoperative observations 
General Examination:    Physical examination: 
Pulse rate: bpm  BP: mm of Hg RR: per min  Weight:  kg 
Systemic examination: 
 CVS:   RS:   Others:             Investigations: 
 Hb:  % FBS/RBS:  ECG:   
 Blood Urea:  Sr.Creatinine:  Urine:  
Preoperative diagnosis :                                    Proposed surgery : 
Premedication   : Inj.Ranitidine 50mg and Inj.Ondansetron 8mg 
ASA grade  : I / II 
Anaesthetic technique : Supraclavicular approach to brachial plexus block using nerve stimulator 
Study protocol : 40 ml of 0.25% Bupivacaine with 100mcg Clonidine or 40 ml of 0.25% 
Bupivacaine with 100mcg Dexmedetomidine  
Time of Injection Onset of sensory blockade Onset of Motor 
Blockade 
Duration  Pulse rate BP(mm of Hg) SpO2% Sedation score 
0 min     
5 min     
10 min     
15 min     
30 min     
60 min     
2hrs     
6hrs     
12hrs     
24hrs     
Duration of 
sensory 
blockade 
 Duration of Motor 
blockade 
 Time &No. of 
rescue 
analgesics in 
post-op 24hrs 
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